指南与共识心境障碍焦虑、强迫与应激相关障碍精神分裂症与精神病性障碍

接受重复经颅磁刺激治疗抑郁、强迫、精神病性及创伤相关障碍患者的合并物质使用评估与管理:德尔菲共识研究与指南

Assessment and Management of Concurrent Substance Use in Patients Receiving Repetitive Transcranial Magnetic Stimulation for Depressive, Obsessive-Compulsive, Psychotic, and Trauma-Related Disorders: A Delphi Consensus Study and Guideline.
指南 / 共识 · Am J Psychiatry · 2025-03-19

针对接受重复经颅磁刺激(rTMS)治疗抑郁、强迫、精神病性或创伤相关障碍的患者,国际24名rTMS专家采用德尔菲法经三轮调查形成共识指南。共识建议不应排除所有物质使用者,而应基于临床不稳定风险因素和使用严重程度进行细致评估,并关注中毒或戒断状态这一最重要安全风险。

要点

  • 不应排除所有物质使用者,应基于临床不稳定风险因素和使用严重程度采取细致方法。
  • 物质使用最重要的安全风险是中毒或戒断状态,数据最多支持不稳定酒精或非医疗兴奋剂使用时的癫痫风险。
  • 尽管无证据表明合并物质使用会降低rTMS疗效,但该领域数据缺乏,需谨慎对待。

核心结论

  • 共识建议不应排除所有物质使用者,而应基于临床不稳定风险因素和使用严重程度进行细致评估。
  • 物质使用最重要的安全风险是中毒或戒断状态,数据最多支持不稳定酒精或非医疗兴奋剂使用时的癫痫风险。
  • 尽管无证据表明合并物质使用会降低rTMS对精神障碍的疗效,但该领域数据缺乏,需谨慎对待。
  • 这些建议可临床实施,并为未来研究提供框架。

研究设计与样本

  • 国际24名rTMS专家组成专家组,代表不同地理区域和亚专业。
  • 采用德尔菲法调查和专家意见,经连续多轮调查、反馈和讨论。
  • 推荐声明在极高(≥80%)同意度下成立。

主要发现

  • 三轮调查和反馈足以对大多数主题达成共识;未能达成共识处,专家组讨论了当前证据基础的局限性。
  • 专家组就筛查、监测、风险评估和缓解提供多项共识推荐,并针对酒精、大麻、兴奋剂和阿片类给出特定考虑。
  • 物质使用最重要的安全风险是中毒或戒断状态,数据最多支持不稳定酒精或非医疗兴奋剂使用时的癫痫风险。
  • 无证据表明合并物质使用会降低rTMS对精神障碍的疗效,但该领域数据缺乏,需谨慎对待。

关键数值与推荐

  • 推荐声明在极高(≥80%)同意度下成立。
  • 不应排除所有物质使用者,而应基于临床不稳定风险因素和使用严重程度进行细致评估。
  • 物质使用最重要的安全风险是中毒或戒断状态,数据最多支持不稳定酒精或非医疗兴奋剂使用时的癫痫风险。
  • 无证据表明合并物质使用会降低rTMS对精神障碍的疗效,但该领域数据缺乏,需谨慎对待。

临床怎么用

  • 这些推荐可临床实施,并为未来研究提供框架。
  • 对接受rTMS治疗原发精神障碍的患者,评估和管理共病物质使用复杂,需要更多关注、标准化和进一步研究。

局限性

  • 当前证据基础存在局限性,专家组在未能达成共识处进行了讨论。
  • 无证据表明合并物质使用会降低rTMS对精神障碍的疗效,但该领域数据缺乏,需谨慎对待。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Limited data are available to inform clinicians on how to manage concurrent substance use in the context of repetitive transcranial magnetic stimulation (rTMS) for the treatment of depressive, obsessive-compulsive, psychotic, or trauma-related disorders. The authors convened an international panel of 24 rTMS experts, representative of different geographic regions and subspecialities, and created a consensus guideline for clinicians and researchers on approaches to concurrent substance use in patients receiving rTMS as treatment for primary psychiatric disorders. METHODS: A Delphi method survey and expert opinion elicited over consecutive rounds of surveys were used, with feedback and discussion after each round. Recommendation statements were established upon very high (≥80%) agreement. RESULTS: Three rounds of surveys and feedback were sufficient to reach a consensus for most topics; where consensus could not be reached, the panel discussed limitations in the current evidence base. Informed by a synthesis of the literature and practice-based evidence, the expert panel provides several consensus recommendations on the topics of screening, monitoring, risk assessment, and mitigation associated with various degrees of substance use, and specific considerations for alcohol, cannabis, stimulants, and opioids. Instead of excluding all people who use substances, a nuanced approach should be taken based on an assessment of risk factors for clinical instability and severity of use. The most important safety risk with substance use is the presence of intoxication or withdrawal states, with the most data supporting seizure risk in unstable alcohol or nonmedical stimulant use. Although there is no evidence of reduced rTMS efficacy for a psychiatric disorder in the presence of concurrent substance use, the lack of data in this area warrants caution. CONCLUSIONS: These recommendations can be readily implemented clinically and provide a framework for future research. In patients receiving rTMS for a primary psychiatric disorder, assessment and management of co-occurring substance use is complex, requiring greater attention, standardization, and further study.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Tang VM, Aaronson S, Abdelghani M, et al. Assessment and Management of Concurrent Substance Use in Patients Receiving Repetitive Transcranial Magnetic Stimulation for Depressive, Obsessive-Compulsive, Psychotic, and Trauma-Related Disorders: A Delphi Consensus Study and Guideline. Am J Psychiatry. 2025. PMID: 40103354. doi:10.1176/appi.ajp.20240403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。